FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026827454> ?p ?o ?g. }

• W2026827454 endingPage "1487" @default.
• W2026827454 startingPage "1481" @default.
• W2026827454 abstract "Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation beyond initial progression among recurrent glioblastoma patients as it is a common, yet unsupported practice in some countries. We analysed outcome among all patients (n=99) who received subsequent therapy after progression on one of five consecutive, single-arm, phase II clinical trials evaluating bevacizumab regimens for recurrent glioblastoma. Of note, the five trials contained similar eligibility, treatment and assessment criteria, and achieved comparable outcome. The median overall survival (OS) and OS at 6 months for patients who continued bevacizumab therapy (n=55) were 5.9 months (95% confidence interval (CI): 4.4, 7.6) and 49.2% (95% CI: 35.2, 61.8), compared with 4.0 months (95% CI: 2.1, 5.4) and 29.5% (95% CI: 17.0, 43.2) for patients treated with a non-bevacizumab regimen (n=44; P=0.014). Bevacizumab continuation was an independent predictor of improved OS (hazard ratio=0.64; P=0.04). The results of our retrospective pooled analysis suggest that bevacizumab continuation beyond initial progression modestly improves survival compared with available non-bevacizumab therapy for recurrent glioblastoma patients require evaluation in an appropriately randomised, prospective trial." @default.
• W2026827454 created "2016-06-24" @default.
• W2026827454 creator A5002201007 @default.
• W2026827454 creator A5011590188 @default.
• W2026827454 creator A5014505996 @default.
• W2026827454 creator A5016437917 @default.
• W2026827454 creator A5021296578 @default.
• W2026827454 creator A5037596103 @default.
• W2026827454 creator A5044465742 @default.
• W2026827454 creator A5045697502 @default.
• W2026827454 creator A5057371623 @default.
• W2026827454 creator A5059965175 @default.
• W2026827454 creator A5062667375 @default.
• W2026827454 creator A5071832983 @default.
• W2026827454 creator A5079356127 @default.
• W2026827454 creator A5081207160 @default.
• W2026827454 creator A5083472710 @default.
• W2026827454 creator A5085537336 @default.
• W2026827454 creator A5088032720 @default.
• W2026827454 date "2012-10-01" @default.
• W2026827454 modified "2023-10-15" @default.
• W2026827454 title "Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients" @default.
• W2026827454 cites W1898063915 @default.
• W2026827454 cites W2001251040 @default.
• W2026827454 cites W2002727873 @default.
• W2026827454 cites W2012562754 @default.
• W2026827454 cites W2021288638 @default.
• W2026827454 cites W2027170726 @default.
• W2026827454 cites W2040905251 @default.
• W2026827454 cites W2043585381 @default.
• W2026827454 cites W2047138539 @default.
• W2026827454 cites W2063622451 @default.
• W2026827454 cites W2086216067 @default.
• W2026827454 cites W2096287682 @default.
• W2026827454 cites W2101711321 @default.
• W2026827454 cites W2127745545 @default.
• W2026827454 cites W2128687105 @default.
• W2026827454 cites W2132697290 @default.
• W2026827454 cites W2148923175 @default.
• W2026827454 cites W2150725676 @default.
• W2026827454 cites W2157500906 @default.
• W2026827454 cites W2158106887 @default.
• W2026827454 cites W2161637607 @default.
• W2026827454 cites W2162643152 @default.
• W2026827454 cites W2163458899 @default.
• W2026827454 cites W2170367762 @default.
• W2026827454 doi "https://doi.org/10.1038/bjc.2012.415" @default.
• W2026827454 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3493761" @default.
• W2026827454 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23037712" @default.
• W2026827454 hasPublicationYear "2012" @default.
• W2026827454 type Work @default.
• W2026827454 sameAs 2026827454 @default.
• W2026827454 citedByCount "81" @default.
• W2026827454 countsByYear W20268274542013 @default.
• W2026827454 countsByYear W20268274542014 @default.
• W2026827454 countsByYear W20268274542015 @default.
• W2026827454 countsByYear W20268274542016 @default.
• W2026827454 countsByYear W20268274542017 @default.
• W2026827454 countsByYear W20268274542018 @default.
• W2026827454 countsByYear W20268274542019 @default.
• W2026827454 countsByYear W20268274542020 @default.
• W2026827454 countsByYear W20268274542021 @default.
• W2026827454 countsByYear W20268274542022 @default.
• W2026827454 countsByYear W20268274542023 @default.
• W2026827454 crossrefType "journal-article" @default.
• W2026827454 hasAuthorship W2026827454A5002201007 @default.
• W2026827454 hasAuthorship W2026827454A5011590188 @default.
• W2026827454 hasAuthorship W2026827454A5014505996 @default.
• W2026827454 hasAuthorship W2026827454A5016437917 @default.
• W2026827454 hasAuthorship W2026827454A5021296578 @default.
• W2026827454 hasAuthorship W2026827454A5037596103 @default.
• W2026827454 hasAuthorship W2026827454A5044465742 @default.
• W2026827454 hasAuthorship W2026827454A5045697502 @default.
• W2026827454 hasAuthorship W2026827454A5057371623 @default.
• W2026827454 hasAuthorship W2026827454A5059965175 @default.
• W2026827454 hasAuthorship W2026827454A5062667375 @default.
• W2026827454 hasAuthorship W2026827454A5071832983 @default.
• W2026827454 hasAuthorship W2026827454A5079356127 @default.
• W2026827454 hasAuthorship W2026827454A5081207160 @default.
• W2026827454 hasAuthorship W2026827454A5083472710 @default.
• W2026827454 hasAuthorship W2026827454A5085537336 @default.
• W2026827454 hasAuthorship W2026827454A5088032720 @default.
• W2026827454 hasBestOaLocation W20268274541 @default.
• W2026827454 hasConcept C126322002 @default.
• W2026827454 hasConcept C141071460 @default.
• W2026827454 hasConcept C143998085 @default.
• W2026827454 hasConcept C167135981 @default.
• W2026827454 hasConcept C188816634 @default.
• W2026827454 hasConcept C207103383 @default.
• W2026827454 hasConcept C2776694085 @default.
• W2026827454 hasConcept C2777802072 @default.
• W2026827454 hasConcept C2780739268 @default.
• W2026827454 hasConcept C2781413609 @default.
• W2026827454 hasConcept C44249647 @default.
• W2026827454 hasConcept C71924100 @default.
• W2026827454 hasConceptScore W2026827454C126322002 @default.
• W2026827454 hasConceptScore W2026827454C141071460 @default.
• W2026827454 hasConceptScore W2026827454C143998085 @default.

• next